dealase

Biotech · Public company · Newtown Square, PA, US

ArriVent BioPharma, Inc.

Ticker AVBP · SEC CIK 0001868279

Track this companyFree. Adds ArriVent BioPharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials55 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed

Pipeline9

Clinical trials5

  • Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.PHASE1 · RECRUITING · started Jul 23, 2026ClinicalTrials.gov NCT07755436 · fetched Nov 12, 2026
  • Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsPHASE3 · RECRUITING · started Dec 17, 2025ClinicalTrials.gov NCT07185997 · fetched Nov 12, 2026
  • A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsPHASE1 · RECRUITING · started Jul 25, 2025ClinicalTrials.gov NCT07066657 · fetched Nov 12, 2026
  • Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 1, 2023ClinicalTrials.gov NCT05607550 · fetched Nov 12, 2026
  • Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 30, 2022ClinicalTrials.gov NCT05364073 · fetched Nov 12, 2026

SEC filings12